Almac IXRS 3 vs YPrime IRT(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Almac IXRS 3

Best for
Sponsors who also use Almac for clinical packaging and distribution and want IRT, forecasting and logistics from one group
What to consider
Almac's IXRS 3 links to Almac's own clinical supply, SupplyWise forecasting and distribution services, and supports direct-to-patient workflows. Almac reports about 2,000 trials run on IXRS. Its public pages give no build timeline, name few randomization methods and show no named security certification.
Read product profile

YPrime IRT

Best for
Sponsors with complex randomization schemes, including minimization, who may also use YPrime eCOA
What to consider
YPrime names more randomization methods than any other vendor here, from permuted blocks to Pocock-Simon minimization, and publishes short build times. Its public IRT page does not describe supply forecasting or direct-to-patient shipping, and we found no named security certification.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Almac IXRS 3 vs YPrime IRT (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featureAlmac IXRS 3YPrime IRT
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Supported

Almac describes simple to complex adaptive designs with enrollment caps, cohorts and blinding protection, but does not name allocation methods.

Source
About this support label

Adaptive designs and blinding protection establish base support; allocation methods are not named.

Extended support

YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.

Source
About this support label

Named methods include permuted blocks, dynamic allocation and minimization.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Extended support

IXRS 3 documents resupply strategy, expiry and depot management, Almac's SupplyWise integrates demand forecasting with the IRT, and an Almac datasheet (Clinical Leader, August 2025) describes direct-to-patient workflows.

Source
About this support label

Resupply and SupplyWise forecasting combine with documented direct-to-patient workflows.

Supported

The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.

Source
About this support label

Inventory and resupply establish base support; forecasting and direct-to-patient shipping are not described.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

Almac describes a controlled-agile build with visual requirements tools, but publishes no build timeline or mid-study change process.

Source
About this support label

Visual study build is described; a build timeline and mid-study change process are not published.

Supported

YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.

Source
About this support label

Build timelines and immediately effective routine changes are stated; uninterrupted live use is not explicit.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Extended support

Almac lists pre-built connectors and REST, SOAP and secure file integrations with EDC, CTMS, clinical supplies and central labs, but has no EDC or eCOA of its own.

Source
About this support label

EDC/CTMS connectors are documented with REST and SOAP integrations.

Supported

YPrime documents integrations with EDC, eCOA, eConsent, CTMS, labs, distribution systems and data lakes, and runs its own eCOA.

Source
About this support label

Trial-system integrations establish base support; an API is not stated in this note.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

Almac states its IXRS University training module is validated and 21 CFR Part 11 compliant; we found no named ISO 27001 or SOC 2 attestation for Clinical Technologies.

Source
About this support label

The Part 11 statement is limited to IXRS University training; ISO/SOC evidence was not found.

Supported

YPrime's trust page lists 21 CFR Part 11, GDPR and HIPAA compliance, but we found no ISO 27001 or SOC 2 attestation.

Source
About this support label

Trial and privacy standards are stated; ISO/SOC attestation evidence was not found.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Extended support

Almac's media kit reports 2,000 clinical trials and over 2 million patients on IXRS, in more than 85 countries (undated kit).

Source
About this support label

Product-specific trial and patient figures are reported across a stated country count.

Supported

YPrime reports 55,000+ sites and 300,000+ patients supported and 20+ years of IRT work, but publishes no study count.

Source

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.